GB201912863D0 - Novel method - Google Patents

Novel method

Info

Publication number
GB201912863D0
GB201912863D0 GBGB1912863.6A GB201912863A GB201912863D0 GB 201912863 D0 GB201912863 D0 GB 201912863D0 GB 201912863 A GB201912863 A GB 201912863A GB 201912863 D0 GB201912863 D0 GB 201912863D0
Authority
GB
United Kingdom
Prior art keywords
novel method
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1912863.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Institute filed Critical Babraham Institute
Priority to GBGB1912863.6A priority Critical patent/GB201912863D0/en
Publication of GB201912863D0 publication Critical patent/GB201912863D0/en
Priority to JP2022515060A priority patent/JP7737979B2/ja
Priority to CN202080077678.3A priority patent/CN115397441A/zh
Priority to KR1020227010908A priority patent/KR20230035210A/ko
Priority to CA3153063A priority patent/CA3153063A1/en
Priority to EP20771603.6A priority patent/EP4025226A1/en
Priority to AU2020341114A priority patent/AU2020341114A1/en
Priority to PCT/GB2020/052148 priority patent/WO2021044175A1/en
Priority to US17/653,554 priority patent/US20220220180A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1912863.6A 2019-09-06 2019-09-06 Novel method Ceased GB201912863D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1912863.6A GB201912863D0 (en) 2019-09-06 2019-09-06 Novel method
JP2022515060A JP7737979B2 (ja) 2019-09-06 2020-09-07 新規法
CN202080077678.3A CN115397441A (zh) 2019-09-06 2020-09-07 新方法
KR1020227010908A KR20230035210A (ko) 2019-09-06 2020-09-07 신규한 방법
CA3153063A CA3153063A1 (en) 2019-09-06 2020-09-07 Novel method
EP20771603.6A EP4025226A1 (en) 2019-09-06 2020-09-07 Novel method
AU2020341114A AU2020341114A1 (en) 2019-09-06 2020-09-07 Novel method
PCT/GB2020/052148 WO2021044175A1 (en) 2019-09-06 2020-09-07 Novel method
US17/653,554 US20220220180A1 (en) 2019-09-06 2022-03-04 Novel method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1912863.6A GB201912863D0 (en) 2019-09-06 2019-09-06 Novel method

Publications (1)

Publication Number Publication Date
GB201912863D0 true GB201912863D0 (en) 2019-10-23

Family

ID=68241092

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1912863.6A Ceased GB201912863D0 (en) 2019-09-06 2019-09-06 Novel method

Country Status (9)

Country Link
US (1) US20220220180A1 (https=)
EP (1) EP4025226A1 (https=)
JP (1) JP7737979B2 (https=)
KR (1) KR20230035210A (https=)
CN (1) CN115397441A (https=)
AU (1) AU2020341114A1 (https=)
CA (1) CA3153063A1 (https=)
GB (1) GB201912863D0 (https=)
WO (1) WO2021044175A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307633A (en) * 2021-04-12 2023-12-01 Univ Pennsylvania Useful preparations in the treatment of spinal muscular atrophy (SBMA)
GB202118073D0 (en) 2021-12-14 2022-01-26 Babraham Inst Novel method and composition comprising IL-2 and a tissue- or organ-specific targeting moiety
GB202202628D0 (en) 2022-02-25 2022-04-13 Babraham Inst Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017060510A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of alzheimer's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102423442B1 (ko) * 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017060510A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of alzheimer's disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AVLES ET AL., BRAIN, 2017
DASHKOFF ET AL., MOLECULAR THERAPY, 2016
MACK: "Remington's Pharmaceutical Sciences", 1982
ROUSE ET AL., IMMUNOBIOLOGY, 2013

Also Published As

Publication number Publication date
JP2022548217A (ja) 2022-11-17
JP7737979B2 (ja) 2025-09-11
CN115397441A (zh) 2022-11-25
CA3153063A1 (en) 2021-03-11
EP4025226A1 (en) 2022-07-13
KR20230035210A (ko) 2023-03-13
US20220220180A1 (en) 2022-07-14
AU2020341114A1 (en) 2022-03-31
WO2021044175A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
GB201907244D0 (en) Method
GB201911286D0 (en) Method
GB201909562D0 (en) Method
GB201913997D0 (en) Method
GB201917742D0 (en) Method
GB201910759D0 (en) Method
GB201912863D0 (en) Novel method
GB201907782D0 (en) Method
GB201900940D0 (en) Method
GB201900647D0 (en) Method
GB201917060D0 (en) Method
IL289648A (en) method
GB201917824D0 (en) Method
GB201917638D0 (en) Method
GB201913970D0 (en) Method
GB201910404D0 (en) Method
GB201909131D0 (en) Method
GB201906768D0 (en) Method
GB201901532D0 (en) Method
GB201918364D0 (en) Novel method
GB201914513D0 (en) Novel Method
GB202007297D0 (en) Method
GB2587925B (en) Method
GB201918290D0 (en) Method
GB201917806D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)